- Details
- Zachary Klaassen and Amanda Myers discuss a single-institution study examining response rates to additional BCG therapy in high-risk non-muscle invasive bladder cancer patients. Dr. Myers presents data analyzing outcomes in both BCG-exposed and BCG-unresponsive populations, providing benchmark response rates to inform clinical trial design. The study demonstrates high success rates with additional...
|
- Details
- Zachary Klaassen and Trinity Bivalacqua discuss sexual dysfunction following radical cystectomy, highlighting significant disparities in how these issues are addressed between male and female patients. Dr. Bivalacqua presents data showing high prevalence of sexual dysfunction after cystectomy in both genders, yet reveals that less than 20% of male patients receive ED treatment post-surgery. The di...
|
- Details
- Zachary Klaassen and Trinity Bivalacqua discuss Cohort B of the CORE-008 trial, which examines cretostimogene in BCG-exposed patients with high-risk non-muscle invasive bladder cancer. The phase 2 multi-cohort, multicenter study focuses on patients who have recurrent high-grade disease but do not meet BCG-unresponsive criteria. The treatment protocol includes a six-week induction course of cretost...
|
- Details
- Trinity Bivalacqua joins Zachary Klaasen to discuss the CORE-008 trial, specifically focusing on cohort A, which examines cretostimogene in high-risk, non-muscle-invasive bladder cancer. The conversation explores this phase II multi-cohort, multicenter, open-label study that targets BCG-naive patients with CIS, with or without papillary disease. The treatment protocol involves a six-week induction...
|
- Details
- Zachary Klaassen and Amanda Myers discuss a US claims analysis examining real-world treatment patterns following BCG induction in non-muscle invasive bladder cancer patients. The study reveals significant underutilization of maintenance BCG therapy, with only a quarter of patients receiving adequate maintenance doses after induction. Their analysis highlights considerable heterogeneity in subseque...
|
- Details
- Shilpa Gupta and Petros Grivas engage in a discussion about lessons learned from immunotherapy use across different cancer types and their application to urothelial cancer. The conversation explores contrasting approaches between kidney cancer, where immunotherapy rechallenge after progression shows no benefit, and melanoma, where immunotherapy rechallenge remains acceptable. They examine the chal...
|
- Details
- Sarah Psutka examines the expanded access program (EAP) for cretostimogene in BCG-unresponsive bladder cancer. The conversation highlights how this oncolytic immunotherapy, which shows a 74% complete response rate and strong durability, is being made available through an EAP designed to gather real-world data from diverse patient populations. Dr. Psutka emphasizes the program's broad eligibility c...
|
- Details
- Tracey Krupski explores the implementation of tele-cystoscopy to improve access to bladder cancer care in resource-challenged areas. Dr. Krupski shares research demonstrating how trained advanced practice providers can perform remote cystoscopies while urologists supervise via video connection, significantly reducing travel burden for patients in underserved regions. The study validates the approa...
|
- Details
- Sam Chang hosts Eugene Pietzak to discuss treatment options for BCG-unresponsive bladder cancer and the challenges of evaluating their comparative effectiveness. Dr. Pietzak emphasizes that while multiple FDA-approved treatments are now available, including pembrolizumab, nadofaragene, and BCG with IL-15 superagonist, comparing their efficacy is complicated by variations in trial designs, surgeon...
|
- Details
- A discussion between Zachary Klaassen and Mark Tyson explores the PIVOT-006 trial examining cretostimogene versus surveillance for intermediate-risk non-muscle invasive bladder cancer. The study evaluates this oncolytic immunotherapy in a new patient population, focusing on both low-grade and high-grade disease that meets specific AUA criteria for intermediate risk. The trial design includes an in...
|
